PALI
Palisade Bio, Inc.
$2.05
-0.03
(-1.44%)
Mkt Cap
355.84M
Volume
3,270,384
52W Range
0.53-2.86
Sector
Healthcare
Beta
1.51
EPS (TTM)
-1.06
P/E Ratio
-7.83
Revenue (TTM)
0
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Palisade Bio, Inc. is a clinical-stage biopharmaceutical firm dedicated to identifying, advancing, and bringing to market orally administered treatments for significant conditions stemming from a compromised gastrointestinal mucosal barrier. The company's primary therapeutic candidate, LB1148, is an oral liquid formulation designed to inhibit digestive enzymes. Its goal is to safeguard gut integrity when the intestine experiences stress due to factors such as diminished blood supply, infections, or surgical procedures. Established in 2005, the company maintains its headquarters in Carlsbad, California.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 250,000 | 0 | 0 | 0 | 15,394 | 260,000 | 260,000 | 16,246 | 10,417 | 18,833 |
| Net Income | (16.78M) | (14.44M) | (12.30M) | (14.26M) | (26.62M) | (10.32M) | (8.35M) | (4.92M) | (15.67M) | (21.07M) | (20.90M) | (22.63M) |
| EPS | -0.30 | -10.19 | -27.01 | -16.53 | -2144.25 | -186.00 | -14.78 | -18.02 | -71.59 | -126.11 | -197.36 | -225.20 |
| Free Cash Flow | (10.85M) | (12.19M) | (11.14M) | (13.37M) | (14.77M) | (4.77M) | (7.26M) | (7.69M) | (13.51M) | (15.78M) | (19.18M) | (12.26M) |
| FCF / Share | -0.19 | -8.61 | -24.42 | -15.19 | -1190.12 | -5.74 | -59.27 | -28.16 | -61.74 | -1890.62 | -181.04 | -122.04 |
| Operating CF | (10.85M) | (12.19M) | (11.13M) | (13.36M) | (14.77M) | (4.77M) | (7.26M) | (7.69M) | (13.42M) | (15.62M) | (18.93M) | (11.71M) |
| Total Assets | 134.34M | 10.88M | 14.05M | 15.76M | 12.51M | 3.02M | 6.58M | 7.68M | 13.88M | 22.60M | 14.95M | 29.84M |
| Total Debt | 71,000 | 169,000 | 369,000 | 404,000 | 199,000 | 1.42M | 288,543 | 5.04M | 0 | 3.71M | 7.93M | 8.79M |
| Cash & Equiv | 133.38M | 9.82M | 12.43M | 12.38M | 10.49M | 713,000 | 5.11M | 5.79M | 6.67M | 15.19M | 4.72M | 12.52M |
| Book Value | 129.38M | 7.49M | 11.31M | 12.48M | 7.37M | (7.10M) | 5.13M | 6.05M | 8.52M | 11.33M | 4.97M | 17.72M |
| Return on Equity | -0.13 | -1.93 | -1.09 | -1.14 | -3.61 | N/A | -1.63 | -0.81 | -1.84 | -1.86 | -4.21 | -1.28 |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (9.60M) | (8.90M) | (2.87M) | (2.78M) | (2.23M) | (3.34M) | (3.49M) | (4.08M) | (3.53M) | (2.97M) | (3.60M) | (3.39M) |
| EPS | -0.05 | -0.06 | -0.38 | -0.58 | -0.46 | -0.57 | -2.32 | -3.32 | -4.59 | -0.51 | -7.38 | -7.93 |
| Free Cash Flow | (3.89M) | (3.14M) | (3.55M) | (1.82M) | (2.33M) | (2.38M) | (3.13M) | (3.50M) | (3.18M) | (2.75M) | (2.66M) | (2.20M) |
| FCF / Share | -0.02 | -0.06 | -0.48 | -0.38 | -0.49 | -0.41 | -0.54 | -0.60 | -4.14 | -0.47 | -5.44 | -0.34 |
| Operating CF | (3.89M) | (3.14M) | (3.55M) | (1.82M) | (2.33M) | (2.38M) | (3.13M) | (3.50M) | (3.18M) | (2.75M) | (2.66M) | (2.20M) |
| Total Assets | 133.31M | 134.34M | 6.97M | 6.67M | 8.19M | 10.88M | 9.34M | 12.87M | 12.65M | 14.05M | 17.07M | 18.29M |
| Total Debt | 0 | 71,000 | 211,000 | 338,000 | 58,000 | 169,000 | 357,000 | 503,000 | 183,000 | 369,000 | 498,000 | 677,000 |
| Cash & Equiv | 132.63M | 133.38M | 5.23M | 5.42M | 7.23M | 9.82M | 8.04M | 11.35M | 11.28M | 12.43M | 15.31M | 16.40M |
| Book Value | 127.36M | 129.38M | 3.21M | 2.62M | 5.33M | 7.49M | 6.61M | 9.95M | 10.06M | 11.31M | 14.08M | 15.80M |
| Return on Equity | -0.08 | -0.07 | -0.89 | -1.06 | -0.42 | -0.45 | -0.53 | -0.41 | -0.35 | -0.26 | -0.26 | -0.21 |
PALI News
Palisade Bio Receives FDA Clearance of IND for PALI-2108 and Plans to Initiate Global Phase 2 ASCENTRA-UC Study in Ulcerative Colitis
Palisade Bio Welcomes Biopharmaceutical Industry Veterans Robert Baltera and Jordan Zwick to its Board of Directors
Palisade Bio to Present on the Potential of PALI-2108 for Fibrostenotic Crohn's Disease at New York Academy of Sciences Symposium
Palisade Bio to Participate in the Jefferies Global Healthcare Conference
Palisade Bio Reports First Quarter 2026 Financial Results and Highlights Continued Clinical Progress of PALI-2108
Palisade Bio Reports First Quarter 2026 Financial Results and Highlights Continued Clinical Progress of PALI-2108
Palisade Bio Reports Additional Phase 1a/b Data Demonstrating Colon-Targeted Exposure and Sustained IC90 Coverage Supporting Once-Daily Dosing in Ulcerative Colitis
Palisade Bio Announces Abstract Selected for Poster Presentation at Digestive Disease Week (DDW) 2026
Palisade Bio, Inc. (NASDAQ:PALI) Receives Consensus Recommendation of “Moderate Buy” from Analysts
Palisade Bio to Present at the Needham & Co. 25th Annual Healthcare Conference